Apellis cites current challenges with Syfovre launch but bright prospects in the long term
Fierce Pharma
FEBRUARY 28, 2024
The first 12 months on the market for Apellis’ geographic atrophy (GA) drug Syfovre have been a roller-coaster ride. The first 12 months on the market for Apellis’ geographic atrophy (GA) drug Syfovre have been a rollercoaster ride. And there’s still more loops to negotiate. | And there are still more loops to negotiate.
Let's personalize your content